Specificity: Detects human amyloid β. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Gantenerumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO gantenerumab is a monoclonal antibody for the treatment of Alzheimer’s disease being developed by Hoffmann-La Roche pharmaceuticals. Gantenerumab binds to and clears aggregated beta amyloid fibers. A phase III clinical trial of gantenerumab was stopped early because of a lack efficacy.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.